Advanced Approaches to Breast & Gynecologic Cancers: Sequencing, Sexual Health, and Hormone Therapy

Join us for a dynamic and evidence-based online course designed to equip healthcare providers with the knowledge and tools to address some of the most nuanced and under-discussed aspects of cancer survivorship care. This comprehensive program brings together leading experts to explore the intersection of sexual health, hormone therapy, and advanced treatment strategies in breast and gynecologic cancers.

Cancer survivorship is evolving, and so must our approach to care. This course offers a unique opportunity to deepen your understanding of the complex challenges faced by patients navigating life after cancer—particularly in the domains of sexual health, menopause, and hormone therapy. 

In addition to survivorship topics, this course will also delve into cutting-edge advancements in metastatic breast cancer treatment, with a dedicated focus on sequencing antibody-drug conjugates (ADCs) in HER2-negative disease. As HER2 expression continues to redefine treatment pathways, participants will explore the clinical significance of HER2-low classifications, the efficacy of ADCs in targeting HER2-expressing cells, and the promise of novel HER2 assays in improving diagnostic precision and therapeutic outcomes.

These topics were originally presented as part of the Miami Cancer Institute Women’s Cancer Symposium:

  • Sexual Health in Patients with Breast Cancer
  • Sequencing Antibody Drug Conjugates in HER2- Metastatic Breast Cancer
  • Hormone Replacement Therapy after Gynecologic Cancers
  • The Pink Elephant in the Room: Breast Cancer, Menopause and Hormone Therapy

Commercial Supporter

Baptist Health gratefully acknowledges the educational grants provided by AstraZeneca, Cooper Surgical, Novartis Pharmaceuticals and Pfizer.

Target Audience

Breast Surgeons, General Surgeons, Reconstructive Surgeons, Obstetricians and Gynecologists, Oncologists, Medical Oncologists, Physiatrists, Radiation Oncologists, Pathologists, Geneticists, Radiologists, General Practitioners, Psychiatrists, Advanced Practice Registered Nurses, Physician Assistants/Physician Associate, Patient Navigators, Nurses, and all other interested healthcare professionals.

Learning Objectives

Sexual Health in Patients with Breast Cancer

  • Describe the range of sexual health issues commonly experienced by breast cancer patients and survivors.
  • Explain the symptoms, causes, and treatment options for Genitourinary Syndrome of Menopause (GSM) in breast cancer survivors.
  • Recognize the signs and contributing factors of Sexual Arousal/Interest Disorder in breast cancer patients.
  • Address sexual health concerns with breast cancer patients. 

Sequencing Antibody Drug Conjugates in HER2- Metastatic Breast Cancer

  •  Analyze the clinical significance of HER2 expression in metastatic breast cancer.
  • Evaluate the efficacy of antibody-drug conjugates (ADCs) in targeting HER2-expressing cells.
  • Discuss the challenges associated with diagnosing "HER2 low" breast cancer.
  • Explore the potential of novel HER2 assays in improving diagnostic accuracy.

The Pink Elephant in the Room: Breast Cancer, Menopause and Hormone Therapy

  • Discuss the scope of the menopause care vacuum for breast cancer survivors and previvors
  • Appreciate and explore the data on HT and breast cancer risk in the general population
  • Outline the guidelines and safety of vaginal hormones for GSM 
  • Analyze the existing data on HT after breast cancer
  • Identify a practical approach to individualization and shared decision making when deciding on HT after breast cancer 

Hormone Replacement Therapy after Gynecologic Cancers

  • Review current guidance on HRT after ovarian, endometrial and cervical cancers
  • Highlight safety of local estrogen use for gynecologic cancer survivors
  • Remind oncology community about need to address menopause symptoms in survivors/previvors
Additional information
Bibliography: 

Sexual Health in Patients with Breast Cancer

  • Li FG, Maheux-Lacroix S, Deans R, et al. Effect of Fractional Carbon Dioxide Laser vs Sham Treatment on Symptom Severity in Women With Postmenopausal Vaginal Symptoms: A Randomized Clinical Trial. JAMA.2021;326(14):1381–1389.
  • Mension E, Alonso I, Anglès-Acedo S, et al. Effect of Fractional Carbon Dioxide vs Sham Laser on Sexual Function in Survivors of Breast Cancer Receiving Aromatase Inhibitors for Genitourinary Syndrome of Menopause: The LIGHT Randomized Clinical Trial. JAMA Netw Open. 2023;6(2):e2255697.
  • Cold S, Cold F, Jensen MB, Cronin-Fenton D, Christiansen P, Ejlertsen B. Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study. J Natl Cancer Inst. 2022 Oct 6;114(10):1347-1354.

Sequencing Antibody Drug Conjugates in HER2- Metastatic Breast Cancer

  • Fu, Z., Li, S., Han, S., Shi, C., & Zhang, Y. (2022). Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal transduction and targeted therapy, 7(1), 93.
  • Modi, S., Jacot, W., Yamashita, T., Sohn, J., Vidal, M., Tokunaga, E., ... & Cameron, D. A. (2022). Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. New England Journal of Medicine, 387(1), 9-20.v
  • Hermansyah, D., Firsty, N. N., Siagian, R. H. N., & Dwinda, N. N. (2024). Intercontinental Comparison of Immunohistochemical Subtypes Among Individuals With Breast Cancer in South-East Asia and South America: A Scoping Systematic Review and Meta-Analysis of Observational Studies. World Journal of Oncology, 15(3), 355.

The Pink Elephant in the Room: Breast Cancer, Menopause and Hormone Therapy

  • Faubion, S. S., Crandall, C. J., Davis, L., El Khoudary, S. R., Hodis, H. N., Lobo, R. A., ... & Wolfman, W. (2022). The 2022 hormone therapy position statement of the North American Menopause Society. Menopause, 29(7), 767-794.
  • Peate, M., Saunders, C., Cohen, P., & Hickey, M. (2021). Who is managing menopausal symptoms, sexual problems, mood and sleep disturbance after breast cancer and is it working? Findings from a large community-based survey of breast cancer survivors. Breast Cancer Research and Treatment, 187, 427-435.
  • Rocca, W. A., Lohse, C. M., Smith, C. Y., Fields, J. A., Machulda, M. M., & Mielke, M. M. (2021). Association of premenopausal bilateral oophorectomy with cognitive performance and risk of mild cognitive impairment. JAMA network open, 4(11), e2131448-e2131448.

Hormone Replacement Therapy after Gynecologic Cancers

  • Taylor, A. (2024). British Gynaecological Cancer Society and British Menopause Society guidelines: Management of menopausal symptoms following treatment of gynaecological cancer.
  • Gorman, M. (2025). Updates in Hormone Replacement Therapy for Survivors of Gynecologic Cancers.
  • Palaia, I. (2024). Hormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: a MITO group survey.
Course Summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 General certificate of attendance
  • 2.00 Nurse Practitioners
  • 2.00 Florida Board of Nursing
Course opens: 
06/01/2025
Course expires: 
05/31/2028

Naomi Dempsey, M.D.
Breast Medical Oncologist
Baptist Health Miami Cancer Institute
Miami, Florida

Lauren Carcas, M.D.
Breast Medical Oncologist
Baptist Health Miami Cancer Institute
Miami, Florida

Corinne D. Menn, D.O.
Board-Certified OB/GYN
Millwood, New York

Shieva Ghofrany, M.D., FACOG
Board-Certified OB/GYN
Stamford, Connecticut

Lauren Carcas, M.D., faculty for this educational activity, is a consultant for Astra Zeneca and Daiichi Sankyo. and has indicated that the presentation or discussion will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.

Naomi Dempsey, M.D., faculty for this educational activity, is an advisor for Lilly, Novartis, Gilead, Pzifer, NeoGenomics, & PrecisCa, and has indicated that the presentation or discussion will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.

Shieva Ghofrany, M.D., FACOG., faculty for this educational activity, is a speaker for Bonafide, & PlusOne, and has indicated that the presentation or discussion will not include off-label or unapproved product usage. All the relevant financial relationships listed for this individual have been mitigated.

Corinne D. Menn, D.O., FACOG, MSCP, faculty for this educational activity, is Director of Clinical Innovation and Education and prescribing physician at Alloy Women’s Health and has indicated that the presentation or discussion will not include off-label or unapproved product usage. All the relevant financial relationships listed for this individual have been mitigated.

John Diaz, M.D., co-director of this educational activity, is a researcher for Merck & Co. and AstraZeneca, and has indicated that the presentation or discussion will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.

Ana Sandoval Leon, M.D., co-director of this educational activity, is an adviser for AstraZeneca, Stemline, and Gilead, and has indicated that the presentation or discussion will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.

Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships with ineligible companies* to disclose.

*Ineligible companies - Companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Disclosure Policy and Disclaimer

Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
              
Baptist Health South Florida designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 General certificate of attendance
  • 2.00 Nurse Practitioners
  • 2.00 Florida Board of Nursing
Please login or register for a Baptist Health CME account to take this course.

Required Hardware/Software

PC/Mac Users
PC/Mac Users

This site is supported on the most recent stable releases of the following browsers:

Click Here to Download Google Chrome
Google Chrome
Microsoft Edge
Microsoft Edge
Safari
Safari
Moxilla Firefox
Mozilla Firefox
Mobile Users
Mobile Users

This site is supported on the following mobile devices:

  • Apple iOS mobile devices running iOS 10 or later
  • Android mobile devices running Android 4.4 or later, with the latest release of Google Chrome or Mozilla Firefox
Technical Support
Technical Support

If you are experiencing technical difficulties or have received an error message, please send an email to [email protected] and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours.